Immatics/$IMTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immatics
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Ticker
$IMTX
Sector
Primary listing
Employees
618
Headquarters
Website
Immatics Metrics
BasicAdvanced
$1.2B
-
-$0.76
1.02
-
Price and volume
Market cap
$1.2B
Beta
1.02
52-week high
$10.95
52-week low
$3.30
Average daily volume
1M
Financial strength
Current ratio
8.803
Quick ratio
8.404
Long term debt to equity
3.038
Total debt to equity
3.684
Interest coverage (TTM)
-90.81%
Profitability
EBITDA (TTM)
-90.994
Gross margin (TTM)
-28.93%
Net profit margin (TTM)
-57.45%
Operating margin (TTM)
-66.92%
Effective tax rate (TTM)
-4.87%
Revenue per employee (TTM)
$244,030
Management effectiveness
Return on assets (TTM)
-9.11%
Return on equity (TTM)
-17.54%
Valuation
Price to revenue (TTM)
7.806
Price to book
2.66
Price to tangible book (TTM)
2.67
Price to free cash flow (TTM)
-5.814
Free cash flow yield (TTM)
-17.20%
Free cash flow per share (TTM)
-1.749
Growth
Revenue change (TTM)
83.61%
Earnings per share change (TTM)
-18.39%
3-year revenue growth (CAGR)
-2.94%
3-year earnings per share growth (CAGR)
14.91%
What the Analysts think about Immatics
Analyst ratings (Buy, Hold, Sell) for Immatics stock.
Bulls say / Bears say
Immatics reported positive Phase 1b ASCO data for anzu-cel, showing a 56% confirmed overall response rate and a median response duration of 12.1 months in heavily pretreated metastatic melanoma patients.
The company closed Q2 2025 with $560.5 million in cash and equivalents, securing funding through the second half of 2027 to support ongoing R&D activities.
Immatics received a milestone payment under its 2023 collaboration with Moderna after Moderna began its first Phase 1 clinical trial, validating Immatics’ XPRESIDENT® target discovery platform.
Revenue from collaboration agreements plunged to $5.5 million in Q2 2025 from $22.0 million a year earlier, highlighting volatility in partnership income and weakening near-term cash flow.
Net loss widened to $82.4 million for Q2 2025 compared to a loss of $21.1 million in Q2 2024, reflecting strong cash outflows from higher R&D costs and foreign exchange losses.
IMTX reported a Q2 2025 loss of $0.66 per share, missing the Zacks Consensus Estimate of a $0.38 loss, and missed revenue by more than 62%, pointing to continued earnings pressure.
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
Immatics Financial Performance
Revenues and expenses
Immatics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immatics stock?
Immatics (IMTX) has a market cap of $1.2B as of October 16, 2025.
What is the P/E ratio for Immatics stock?
The price to earnings (P/E) ratio for Immatics (IMTX) stock is 0 as of October 16, 2025.
Does Immatics stock pay dividends?
No, Immatics (IMTX) stock does not pay dividends to its shareholders as of October 16, 2025.
When is the next Immatics dividend payment date?
Immatics (IMTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Immatics?
Immatics (IMTX) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.